// Biotech and Pharma Therapeutics
UnitedHealth CEO says no copay for insulin, other critical drugs from 2023 – PharmaLive
UnitedHealth CEO says no copay for insulin, other critical drugs from 2023
Gilmore O’Neill picked a bad time to become a biotech CEO. He’s confident Editas has the goods
Gilmore O’Neill probably couldn’t have picked a worse time | Editas’ new CEO Gilmore O’Neill has already checked off a few items on his to do list in his first six weeks, including hiring a chief medical officer. Fierce Biotech caught up with him and his new CMO to find out what’s next.
Marinus parts with priority review voucher, selling skip-the-line pass to Novo Nordisk for $110M
Marinus Pharmaceuticals is using a priority review voucher granted four months ago as a financial life preserver, selling the accelerated review pass designated for rare pediatric diseases to Novo | Marinus is selling off a priority review voucher to Novo Nordisk for $110 million. The company plans…
Novartis looking for new homes for midphase asthma, eye disease and NASH assets after pipeline review
Novartis has put (PDF) a trio of midphase drugs up for partnering. | Novartis has put a trio of midphase drugs up for partnering. After performing its annual portfolio review, the Swiss Big Pharma decided to bring in outside support to drive development of treatments for retinitis pigmentosa, asthma…
// 4th Industrial Revolution
Lack of payment pathway clarity hinders digital therapeutics, analysts say
The report warns of a sector beset by payment issues, “snake oil” and “middling adoption.”
What the POTS shutdown will mean for faxing in the healthcare industry
The FCC is officially closing the door on analog/copper POTS lines. Read what this means for the healthcare industry.
How California is building the nation’s largest healthcare data exchange
The state of California recently embarked on an ambitious endeavor. Using hundreds of millions of dollars in public funding, the nation’s largest state plans to connect its hospitals and healthcare providers through a statewide health information exchange.
How 4 health systems are using AI, data analytics and machine learning
Hospitals are using AI, data analytics and machine learning to improve health outcomes, produce predictive clinical insights and improve patient care. Here are four artificial intelligence projects health systems have recently created and deployed as reported by Becker’s Hospital Review:
Artificial Intelligence-related deals significantly decreased in the pharmaceutical industry in H1 2022
Deals relating to AI in the pharmaceutical sector have seen a decrease of 47.8% from H1 2021 to H1 2022, an analysis of GlobalData’s deals database reveals.
The “only AI-powered 24/7 mental health solution” raises $20M - MedCity News
Wysa, a company that provides AI-driven mental health support through an app, received $20 million in series B funding. The company differentiates itself from competitors by providing support 24/7, its CEO claims.
// Business & Markets
Vertex signs agreement to acquire ViaCyte for $320m
Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of ViaCyte in a deal totalling $320m in cash.
Biotech earnings arrive after dreadful 6 months, but upcoming readouts offer hope to analysts
With signs that biotech’s nosedive may be starting to level off, will the sector’s big players use their second-quarter earnings results to point to green shoots? | With signs that biotech’s nosedive may be starting to level off, will the sector’s big players use their second-quarter earnings result…
Morgan Health makes $30M investment in Centivo
Morgan Health, the healthcare arm of JPMorgan Chase, will invest $30 million in Centivo, a health plan for self-funded employers. | Morgan Health, the healthcare arm of JPMorgan Chase, will invest $30 million in Centivo, a health plan for self-funded employers.
Nestlé wagers $41M on Enterome’s preclinical food allergy and IBD prospect
Nestlé Health Science has returned to the deal table once again,
Zymeworks plots corporate move from Canada to tax-friendly Delaware
After launching in Vancouver nearly 20 years ago, Zymeworks is looking to shave a few dollars off its tax bill, announcing plans to become a Delaware corporation. | Zymeworks is shifting its corporate home base from Canada to tax-friendly Delaware in a bid to reduce costs. The move is expected to b…
// Legal & Regulatory
Biogen gains prominent ally in bid for Supreme Court to review Tecfidera patent case
After the U.S. | After the U.S. Court of Appeals for the Federal Circuit scuttled Biogen’s bid for a rehearing on its Tecfidera patent case in March, the big biotech was left with few options but to appeal to the Supreme Court. Now, as the high court considers whether to take up the case, Biogen has…
FDA Regulatory News and Trends
Welcome to the latest issue of FDA Regulatory News and Trends, designed to help you identify significant legal developments and navigate the evolving…
Parents become drug developers to save their children’s lives
Maggie Carmichael wasn’t developing like other kids. As a toddler, she wasn’t walking and had a limited vocabulary for her age.
Novo strikes $110M deal for regulatory fast pass
The Danish drugmaker will buy a priority review voucher from Marinus Pharmaceuticals, the latest in a string of similarly priced purchases.
// Research & Development
NYU surgeons successfully implant two pig hearts into brain-dead patients – PharmaLive
Physicians at New York University’s (NYU) Langone Health have successfully implanted pig hearts into the bodies of patients that were living but no longer showed neural function in a process called xenotransplantation.
New gene identified that contributes to progression to type 1 diabetes - California News Times
Dr. Sharad Purohit and Paul Tran, an MD / PhD student.Credits: Michael Holahan, Augusta University Scientists report that the combination of an pro-inflammatory pair of receptors called CCR2 and its ligand, CCL-2, increases the risk of developing type 1 diabetes. In this autoimmune disorder, which u…
Why brain stimulation should not be overlooked as an antidepressant treatment for older adults
In the U.S., rTMS was cleared by the Food and Drug Administration (FDA) in 2008 to treat patients suffering from treatment resistant depression, or in other words, patients who do not respond to standard antidepressants. It has since been approved or recommended in several other countries. The main…
Drug Recommendation System for Diabetes Using a Collaborative Filtering and Clustering Approach: Development and Performance Evaluation
Background: Diabetes is a public health problem worldwide. Although diabetes is a chronic and incurable disease, measures and treatments can be taken to control it and keep the patient stable. Diabetes has been the subject of extensive research, ranging from disease prevention to the use of technolo…
Sesen slams brakes on phase 3 bladder cancer program to save cash as it looks for off-ramp
Sesen Bio is pumping the brakes on its phase 3 bladder cancer program. | Sesen Bio is pumping the brakes on its phase 3 bladder cancer program. After weighing up what it will take to get Vicineum to market, the biotech has paused clinical development in the U.S. to preserve the cash that could be ke…
Lowering insulin prices isn’t the (only) answer to helping patients with diabetes - MedCity News
It is time to shift the conversation, incentives, and policy solutions to help people improve their health and get off of medications—not just make them cheaper.
Fauci to retire by end of biden’s term
Dr. Anthony Fauci, who has helped shepherd Americans through the pandemic amid heavy fire from critics, plans to retire as the director of the National Institute of Allergy and Infectious Diseases by the end of President Joe Biden’s term.
Health Care Renovation
The changes aren’t a major reconsideration of the health care system in the U.S., as Medicare for all would be. Instead, Democrats in Congress have crafted smaller solutions to gaps in the current system.
Australia Subsidizes Glucose Monitoring Devices
The Australian government is turning to a digital solution to address a prevalent health issue: Type 1 diabetes. The plan, under the helm of the National Diabetes Services Scheme (NDSS), is to give…
Medicare pays $700M+ annually for discarded drugs. That’s about to change
Data from 2020 show the Centers for Medicare and Medicaid Services paid almost $720 million for discarded drugs from single-use vials, and it’s been doing this for years. But with the passage of the Infrastructure Investment and Jobs Act last November, drug manufacturers beginning next year will be…